New study tests if delaying radiation improves brain tumor control

NCT ID NCT06649058

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether giving systemic therapy first, followed by focused radiation (stereotactic radiosurgery), can better control brain metastases. About 316 adults with brain metastases that are low-risk will receive standard cancer drugs, then some will get radiation to all or only growing tumors. The goal is to see if this sequence improves disease control and safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
systemic therapy (standard cancer drugs) and stereotactic radiosurgery (focused radiation)
What this could lead to
If successful, this could show that adding focused radiation after initial drug therapy improves control of brain metastases and delays disease progression.
What could go wrong
This is a mid-stage trial with 316 participants, so results are not yet proven. The benefit may be small or limited to certain patients, and radiation carries risks like brain swelling or damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The University of Texas MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.